Literature DB >> 8110618

Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events, and mortality.

P Rubba, P Pauciullo, M Mancini.   

Abstract

Hypercholesterolemia has been associated with an increase in vascular tone, mainly because of an impairment of endothelium-dependent relaxation. This endothelial dysfunction occurs before any definite atherosclerotic lesion is demonstrated. In both animal models and humans the correction of hypercholesterolemia has been associated with hemodynamic improvement. Several controlled trials have demonstrated that long-term treatment with cholesterol-lowering drugs is effective in blocking progression and in some cases in inducing regression of angiographically detected arterial lesions. Arteriographies produce a negative image of the arterial lumen but do not provide sufficient information on vessel wall status. Noninvasive B-mode ultrasound has allowed a direct visualization of the arterial wall in superficial vascular districts, such as the carotid bifurcation. Wall and lesion measures are increasingly used as end points for clinical trials of antiatherosclerotic drugs. In secondary prevention, cholesterol reduction is associated with a lower incidence of coronary heart disease, although the cholesterol reduction should be at least 8-9% to have an impact on total mortality.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8110618     DOI: 10.1007/bf00878928

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  61 in total

1.  Clofibrate and niacin in coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1975-01-27       Impact factor: 56.272

Review 2.  The value of lowering cholesterol after myocardial infarction.

Authors:  J E Rossouw; B Lewis; B M Rifkind
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

3.  Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.

Authors:  J A Vita; C B Treasure; E G Nabel; J M McLenachan; R D Fish; A C Yeung; V I Vekshtein; A P Selwyn; P Ganz
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

4.  Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates.

Authors:  F W Sellke; M L Armstrong; D G Harrison
Journal:  Circulation       Date:  1990-05       Impact factor: 29.690

5.  Measurement variability of carotid atherosclerosis: real-time (B-mode) ultrasonography and angiography.

Authors:  D H O'Leary; F A Bryan; M W Goodison; M D Rifkin; R Gramiak; M Ball; M G Bond; R A Dunn; B B Goldberg; J F Toole
Journal:  Stroke       Date:  1987 Nov-Dec       Impact factor: 7.914

6.  Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.

Authors:  L Cashin-Hemphill; W J Mack; J M Pogoda; M E Sanmarco; S P Azen; D H Blankenhorn
Journal:  JAMA       Date:  1990-12-19       Impact factor: 56.272

7.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

8.  Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial.

Authors:  R G Duffield; B Lewis; N E Miller; C W Jamieson; J N Brunt; A C Colchester
Journal:  Lancet       Date:  1983-09-17       Impact factor: 79.321

9.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Authors:  D H Blankenhorn; S A Nessim; R L Johnson; M E Sanmarco; S P Azen; L Cashin-Hemphill
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

10.  Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis.

Authors:  A M Zeiher; H Drexler; H Wollschläger; H Just
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.